Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. / Viby, Niels-Erik; Isidor, Marie Sophie; Buggeskov, Katrine B; Poulsen, Steen Seier; Hansen, Jacob B.; Kissow, Hannelouise.
In: Endocrinology, Vol. 154, No. 12, 2013, p. 4503-4511.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice
AU - Viby, Niels-Erik
AU - Isidor, Marie Sophie
AU - Buggeskov, Katrine B
AU - Poulsen, Steen Seier
AU - Hansen, Jacob B.
AU - Kissow, Hannelouise
PY - 2013
Y1 - 2013
N2 - The incretin hormone glucagon-like peptide-1 (GLP-1) is an important insulin secretagogue and GLP-1 analogues are used for the treatment of type 2 diabetes. GLP-1 displays anti-inflammatory and surfactant releasing effects. Thus, we hypothesize that treatment with GLP-1 analogues will improve pulmonary function in a mouse model of obstructive lung disease. Female mice were sensitized with injected ovalbumin and treated with GLP-1 receptor (GLP-1R) agonists. Exacerbation was induced with inhalations of ovalbumin and lipopolysaccharide. Lung function was evaluated with measurement of enhanced pause (Penh) in a whole body plethysmograph. mRNA levels of GLP-1R, surfactants (SFTPs), and a number of inflammatory markers were measured. GLP-1R was highly expressed in lung tissue. Mice treated with GLP-1R agonists had a noticeably better clinical appearance than the control group. Penh increased dramatically at day 17 in all control mice but the increase was significantly less in the groups of GLP-1R agonist treated mice (p
AB - The incretin hormone glucagon-like peptide-1 (GLP-1) is an important insulin secretagogue and GLP-1 analogues are used for the treatment of type 2 diabetes. GLP-1 displays anti-inflammatory and surfactant releasing effects. Thus, we hypothesize that treatment with GLP-1 analogues will improve pulmonary function in a mouse model of obstructive lung disease. Female mice were sensitized with injected ovalbumin and treated with GLP-1 receptor (GLP-1R) agonists. Exacerbation was induced with inhalations of ovalbumin and lipopolysaccharide. Lung function was evaluated with measurement of enhanced pause (Penh) in a whole body plethysmograph. mRNA levels of GLP-1R, surfactants (SFTPs), and a number of inflammatory markers were measured. GLP-1R was highly expressed in lung tissue. Mice treated with GLP-1R agonists had a noticeably better clinical appearance than the control group. Penh increased dramatically at day 17 in all control mice but the increase was significantly less in the groups of GLP-1R agonist treated mice (p
U2 - 10.1210/en.2013-1666
DO - 10.1210/en.2013-1666
M3 - Journal article
C2 - 24092637
VL - 154
SP - 4503
EP - 4511
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0013-7227
IS - 12
ER -
ID: 57754734